


## AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions and listing of claims in the application.

### Listing of Claims


1. (currently amended) A method of ~~treating or preventing or inhibiting solid tumor growth~~ a neoplasia disease sensitive to the combination in a mammal, the method comprising administering to a mammal in need thereof ~~of treatment for a neoplasia disease~~ a therapeutically effective amount of a compound of the formula:











wherein X and Y are the same or different halo group; R is H or lower alkyl; and pharmaceutically acceptable salts thereof; together with a chemotherapeutic agent selected from the group consisting of cyclophosphamide, methotrexate, fluorouracil, paclitaxel, mitomycin, leuprolide, leucovorin, carboplatin, dacarbazine, vinblastine, etoposide, ifosfamide, dactinomycin, and carmustine.

2. (cancelled)

3. (previously presented) A method according to claim 1 wherein the compound is selected from the group consisting of:








4. (cancelled)




5. (currently amended) A method of ~~treating or preventing or inhibiting solid tumor growth a neoplasia disease sensitive to the combination~~ in a mammal, the method comprising administering to a mammal in need thereof of treatment for a neoplasia disease a therapeutically effective amount of a compound of the formula:









wherein X and Y are the same or different halo group; R is H or lower alkyl; or a pharmaceutically acceptable salt thereof; together with a chemotherapeutic agent selected from the group consisting of cyclophosphamide, methotrexate, fluorouracil, paclitaxel, mitomycin, leuprolide, leucovorin, carboplatin, dacarbazine, vinblastine, etoposide, ifosfamide, dactinomycin, and carmustine.

6. (cancelled)

7. (previously presented) A method according to claim 5 wherein the compound is selected from the group consisting of:








8. (cancelled).

9. (currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound ~~corresponding to claim 1~~ of the formula:



wherein X and Y are the same or different halo group; R is H or lower alkyl; or a pharmaceutically acceptable salt thereof, a chemotherapeutic agent selected from the group consisting of cyclophosphamide, methotrexate, fluorouracil, paclitaxel, mitomycin, leuprolide, leucovorin, carboplatin, dacarbazine, vinblastine, etoposide, ifosfamide, dactinomycin, and carmustine; and a pharmaceutically acceptable carrier.

Claims 10-13 (cancelled).

14. (new) A pharmaceutical composition as set forth in claim 9, wherein the composition comprises a therapeutically effective amount of a compound selected from the group consisting of:

